Start Dup15q and CAMK2 expertise centers
Recently, two new expertise have been launched under ENCORE! We can now welcome patients with CAMK2 Syndrome and Dup15q Syndrome at our ENCORE expertise center.
Continue ReadingNEPTUNE study for Angelman Syndrome completed
ENCORE participated in the international NEPTUNE study of the pharmaceutical company OVID. Four Dutch children participated in the study. The desired number of participants has now been reached, so no more children are enrolled. We expect the first results in early 2021.
Continue ReadingNEPTUNE TRIAL
Phase 3 clinical study of the effect of the drug OV101 (Gaboxadol) in children with Angelman Syndrome
Continue ReadingEXCEL TRIAL
Phase 2 and 3 clinical study of the effect of Lamotrigine on cognition in patients with NF1
Continue ReadingCOVANT STUDY
Cognitive variability in NF1 and TSC monozygotic twins
Continue ReadingGWPCARE6 TRIAL
Phase 3 clinical study of the effect of Cannabidiol on epilepsy in patients with TSC
Continue ReadingVEP-NF1 study
Visual information processing in adults with and without Neurofibromatosis 1
Continue ReadingRAPIT TRIAL
Phase 2 and 3 clinical study of the effect of the drug Sirolimus in children with TSC.
Continue ReadingRATE TRIAL
Fase 2 en 3 klinische studie naar het effect van het medicijn Sirolimus in kinderen met TSC.
Continue ReadingSIMCODA TRIAL
Phase 3 clinical study of the effect of the drug Simvastatin in children with NF1
Continue Reading